Saso Cemerski, Ph.D. joined MRL Boston in 2014 and has contributed to advancing Merck’s anti-LAG-3 antibody (MK-4280) into Ph1 clinical trial. He is invested in co-leading Merck’s MK-1454 program from target validation to Ph1 clinical trial entry. Saso is closely involved with other accelerated MRL preclinical programs targeting novel and emerging molecules
critical for mounting strong immune anti-tumour responses. Saso obtained his Ph.D. in immunology in Toulouse, France. He did his postdoctoral training at Washington University in Saint Louis and worked at Xencor (Monrovia, CA) and BMS (Lawrenceville, NJ) prior to joining MRL.